Calidi Biotherapeutics, Inc.
CLDI · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | 0.00 | 0.04 |
| FCF Yield | -214.97% | -113.82% | -15.84% | -2.84% |
| EV / EBITDA | -0.34 | -1.22 | -3.67 | -30.05 |
| Quality | ||||
| ROIC | -238.46% | -1,695.44% | 66.36% | 59.94% |
| Gross Margin | 0.00% | 0.00% | -508.89% | 79.06% |
| Cash Conversion Ratio | 0.89 | 0.92 | 0.52 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | – | 765,641.37% |
| Free Cash Flow Growth | 28.50% | -102.08% | -70.95% | -54.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.13 | -0.21 | -0.22 | -0.32 |
| Interest Coverage | -23.34 | -7.73 | -146.38 | -17.07 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -836.07 | -2,829.42 | -2,422.98 |